Study Shows Unfractionate Heparin Just As Effective as Low-Molecular Weight Heparin in the Treatmetn of Venous Thromboembolism
"Fixed-dose subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin for initial treatment of patients with venous thromboembolism and is suitable for treatment at home," concluded Dr. Kearon, who is a physician at Hamilton Health Sciences.
"In addition, the results of this study question the value of APTT monitoring in patients who are treated with currently recommended doses of unfractionated heparin."
A six-day course of treatment with the new low-molecular-weight heparin is estimated to cost about $712, compared to $37 using unfractionated heparin.
Read more from the feaure report in Science Daily.
Comment Preview